What is Tesamorelin?
Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH), consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification for enhanced stability. It stimulates the pituitary gland to secrete growth hormone and has been researched extensively in models of GH deficiency and visceral adiposity.
Tesamorelin Structure
| Peptide Name | Tesamorelin |
| Synonyms | TH9507, GHRH analog |
| Sequence | Trans-3-hexenoic acid – full 44-AA GHRH sequence analog |
| Molecular Weight | Approx. 5,135 g/mol |
Tesamorelin Research
1. Tesamorelin and Visceral Fat Reduction
Clinical research has demonstrated significant reductions in visceral adipose tissue (VAT) with Tesamorelin administration, making it a key compound in metabolic and lipodystrophy research.
2. Tesamorelin and IGF-1 Levels
Studies consistently show Tesamorelin elevates IGF-1 levels in a GH-dependent manner, providing a measurable biomarker for its activity in research protocols.
3. Tesamorelin and Cognitive Research
Emerging data from aging population studies suggests Tesamorelin may influence cognitive function, potentially via GH/IGF-1 axis effects on hippocampal volume and function.
Future Tesamorelin Research
Future investigations are focused on NAFLD/NASH models, cognitive aging, and combined peptide protocols with GHRPs.
Tesamorelin Resources
- Falutz J, et al. – Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM, 2007.
- Stanley TL, et al. – Effects of tesamorelin on non-alcoholic fatty liver disease. Lancet HIV, 2019.


Reviews
There are no reviews yet.